Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VCYT vs GRAL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GRAL Captures Overall Composite Edge (54.5 HOLD vs 49.1 HOLD), While VCYT Leads 5–1 on Growth & Valuation Pillars

GRAL Overall Winner 6-Pillar Tally: VCYT 5 – 1 GRAL Matrix Metrics: VCYT 4 – 6 GRAL

As of Nov 16, 2026, GRAIL, Inc. (GRAL) captures the overall head-to-head institutional edge over Veracyte, Inc. (VCYT) on higher Unified Composite conviction (54.5/100 HOLD vs. 49.1/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples), while VCYT wins 5–1 across the 6-pillar growth and valuation breakdown. VCYT trades at $24.01 (15.3x Forward P/E, 15.0% operating margin) versus GRAL at $105.60 (1.1x Forward P/E, -332.0% operating margin).

  • Growth vs. Quality Trade-Off: GRAL earns the overall head-to-head edge with a stronger Unified Composite Score (54.5/100 HOLD vs. VCYT 49.1/100 HOLD) and 3.09β · 99% Vol risk profile, whereas VCYT leads top-line expansion (+15.1% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile GRAL is in a Breakdown options structure phase (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VCYT vs GRAL
VCYT NASDAQ
Veracyte, Inc.
Services-Medical Laboratories
$24.01
-1.32% 1D
Market Cap $2.0B
TTM Revenue $582M
Forward P/E 15.3x
Beta / 30D Vol 3.01β · 199% Vol
Unified Composite Score
49.1 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 57.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.8%), weak momentum, RSI 28
RSI-14: 27.8 · SMA20: $39.20 · SMA50: $41.79
GRAL NASDAQ Head-to-Head Winner
GRAIL, Inc. Common Stock
Services-Medical Laboratories
$105.60
-8.88% 1D
Market Cap $5.2B
TTM Revenue $167M
Forward P/E 1.1x
Beta / 30D Vol 3.09β · 99% Vol
Unified Composite Score
54.5 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 57.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 37.7 · SMA20: $132.32 · SMA50: $121.37

6-Pillar Scorecard Institutional Category Breakdown (VCYT 5 – 1 GRAL)

Columns: Metric · VCYT · GRAL
1. Valuation Multiples GRAL
Forward P/E 15.3x 1.1x
Trailing P/E 15.8x 1.1x
PEG Ratio N/M N/M
EV / Revenue 3.1x 31.6x
2. Growth & Scale VCYT
Revenue Growth (YoY) +15.1% +3.7%
Earnings Growth (YoY) +58.3% +0.0%
TTM Revenue (USD) $582M $167M
Market Cap $2.0B $5.2B
3. Profitability & Quality VCYT
Gross Margin 74.2% 46.7%
Operating Margin 15.0% -332.0%
Net Profit Margin 21.8% -243.8%
Return on Equity (ROE) 9.4% -17.3%
4. Balance Sheet & Cash Flow VCYT
Cash Generation (TTM) $162M -$312M
Cash Flow Margin 27.8% N/A
Net Cash / Leverage $159M Net Cash $57M Net Debt (0.03x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VCYT
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 197.3% (47th %ile) 93.0% (53rd %ile)
Put/Call OI Skew 0.01x (Call-Skewed) 0.81x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat VCYT
OpEx & R&D Intensity 59.2% of Rev ($344M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VCYT (4) vs GRAL (6)
Institutional Metric VCYT GRAL Criterion Row Edge
Market Capitalization
Scale
$2.0B $5.2B Larger Scale GRAL
Trailing P/E Ratio
Valuation
15.8x 1.1x Lower Multiple GRAL
Forward P/E Ratio
Valuation
15.3x 1.1x Lower Multiple GRAL
Revenue Growth (YoY)
Growth
+15.1% +3.7% Higher Growth VCYT
Operating Margin (TTM)
Profitability
15.0% -332.0% Higher Margin VCYT
Net Profit Margin
Profitability
21.8% -243.8% Higher Margin VCYT
Return on Equity (ROE)
Capital Efficiency
9.4% -17.3% Higher ROE VCYT
52-Week Range Position
Momentum
5% ($22–$61) 51% ($42–$166) Stronger Trend GRAL
Beta / 30D Volatility
Risk Regime
3.01β · 199% Vol 3.09β · 99% Vol Lower Realized Risk GRAL
Unified Institutional Score
Composite Signal
49.1 / 100 (HOLD) 54.5 / 100 (HOLD) Higher Composite GRAL
Trailing 12M Revenue (USD)
Operating Scale
$582M $167M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
74.2% 46.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.1x EV/Rev N/M PEG · 31.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$162M ($159M Net Cash) -$312M ($57M Net Debt (0.03x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GRAL +33.96 pp
VCYT: -44.32% · GRAL: -10.36%
3M Horizon GRAL +93.9 pp
VCYT: -42.94% · GRAL: +50.96%
6M Horizon GRAL +114.63 pp
VCYT: -37.6% · GRAL: +77.03%
1Y Horizon GRAL +66.7 pp
VCYT: -39.78% · GRAL: +26.92%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VCYT Revenue GRAL Revenue VCYT Op. Margin GRAL Op. Margin Margin Leader
FY2018 $90M N/A -24.2% N/A VCYT
FY2019 $120M N/A -12.6% N/A VCYT
FY2020 $120M N/A -30.1% N/A VCYT
FY2021 $220M N/A -37.3% N/A VCYT
FY2022 $300M N/A -13.9% N/A VCYT
FY2023 $360M $90M -23.8% -1627.6% VCYT
FY2024 $450M $130M 3.6% -1743.0% VCYT
FY2025 $520M $150M 11.2% -382.0% VCYT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VCYT BREAKDOWN
99d in phase · OBV DISTRIBUTION
Current IV 197.3%
IV Percentile 47th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GRAL BREAKDOWN
12d in phase · OBV DISTRIBUTION
Current IV 93.0%
IV Percentile 53rd %ile
Put/Call OI Skew 0.81x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact GRAL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VCYT Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $2.0B market capitalization and 15.0% operating margin.
OpEx & R&D Reinvestment 59.2% of Rev ($344M)
90D Engineering Disclosures 0 Published
GRAL Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $5.2B market capitalization and -332.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VCYT vs GRAL Key Questions & Quantitative Answers

As of Nov 16, 2026, GRAIL, Inc. (GRAL) captures the overall head-to-head institutional edge over Veracyte, Inc. (VCYT) on higher Unified Composite conviction (54.5/100 HOLD vs. 49.1/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples), while VCYT wins 5–1 across the 6-pillar growth and valuation breakdown. VCYT trades at $24.01 (15.3x Forward P/E, 15.0% operating margin) versus GRAL at $105.60 (1.1x Forward P/E, -332.0% operating margin). Growth vs. Quality Trade-Off: GRAL earns the overall head-to-head edge with a stronger Unified Composite Score (54.5/100 HOLD vs. VCYT 49.1/100 HOLD) and 3.09β · 99% Vol risk profile, whereas VCYT leads top-line expansion (+15.1% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile GRAL is in a Breakdown options structure phase (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VCYT leads the Growth & Scale pillar: VCYT posts +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin), compared with GRAL at +3.7% YoY revenue growth and +0.0% YoY earnings growth on $167M TTM revenue (46.7% gross margin, -332.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VCYT cumulative revenue shifted +477.8% while GRAL shifted +66.7%. In operating R&D and SG&A reinvestment, VCYT deploys 59.2% of Rev ($344M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GRAL.

GRAL screens cheaper on headline valuation multiples. VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin), whereas GRAL trades at 1.1x Forward P/E, 1.1x Trailing P/E, N/M PEG, and 31.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VCYT (9.4% ROE) versus GRAL (-17.3% ROE) capital efficiency.

In options market volatility and institutional positioning, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 199% Vol realized risk). By comparison, GRAL carries 93.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), a 0.81x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.09β · 99% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.